BPG is committed to discovery and dissemination of knowledge
Featured Articles
10/18/2022 9:30:43 AM | Browse: 389 | Download: 1094
 |
Received |
|
2022-07-02 18:19 |
|
Peer-Review Started |
|
2022-07-02 18:20 |
|
First Decision by Editorial Office Director |
|
2022-08-01 00:37 |
|
Return for Revision |
|
2022-08-01 00:37 |
|
Revised |
|
2022-09-24 20:39 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-10-10 03:28 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-10-10 14:58 |
|
Articles in Press |
|
2022-10-10 14:58 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-10-12 02:36 |
|
Publish the Manuscript Online |
|
2022-10-18 08:29 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Alexa R Weingarden, John Gubatan, Sundeep Singh, Tatiana Clorice Balabanis, Akshar Patel, Arpita Sharma and Aida Habtezion |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Alexa R Weingarden, MD, PhD, Academic Fellow, Consultant Physician-Scientist, Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Alway Building, Room M211, 300 Pasteur Drive, Stanford, CA 94305, United States. aweingar@stanford.edu |
| Key Words |
Immune checkpoint inhibitors; Immune checkpoint inhibitor-mediated colitis; Immune-related adverse events; Overall survival |
| Core Tip |
Immune checkpoint inhibitor-mediated colitis (IMC) is a common adverse event following immune checkpoint inhibitor (ICI) therapy for cancer. We sought to determine the association of IMC with overall survival (OS) and progression-free survival (PFS) among cancer patients treated with ICI and identify clinical predictors of IMC. We performed a retrospective case-control study including 64 ICI users who developed IMC. In multivariate logistic regression analysis, IMC was significantly associated with a higher OS but not PFS. IMC was significantly associated with OS greater than 12 mo. Vitamin D supplementation was associated with increased risk of IMC. |
| Publish Date |
2022-10-18 08:29 |
| Citation |
Weingarden AR, Gubatan J, Singh S, Balabanis TC, Patel A, Sharma A, Habtezion A. Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival. World J Gastroenterol 2022; 28(39): 5750-5763 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i39/5750.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i39.5750 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
